Fosamax Osteonecrosis of the Jaw Causation: How Fosamax triggers Osteonecrosis of the Jaw pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Principles to Specific Pharmaceutical Concerns

The Immunodeficiency Foundation has long provided foundational understanding of how the body maintains equilibrium and responds to various internal and external challenges. This heritage emphasizes preserving scientific records that illuminate the complexities of human health, often focusing on broad physiological principles and the body's adaptive mechanisms. The same principles that govern the body's response to pathogens or environmental stressors also apply to the introduction of pharmaceutical agents into the system. As we move from this broad heritage, we now consider a scenario where a widely prescribed medication, intended to address a common health issue, becomes a focal point for health inquiry. The concern shifts from general population health to the specific circumstances of individuals who may have prolonged or heightened exposure to such agents. This pivot acknowledges that the body's handling of external substances, whether encountered in daily life or through therapeutic use, is a continuum of the same biological principles.

Bridging to Fosamax and Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves the death of jawbone tissue and can occur spontaneously, though it is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology linking Fosamax to ONJ is complex and involves multiple mechanistic pathways.

Mechanisms of Fosamax-Induced Osteonecrosis of the Jaw

The primary mechanism by which Fosamax triggers ONJ relates to its pharmacological action as a bisphosphonate. Bisphosphonates, including alendronate, inhibit osteoclast-mediated bone resorption. This suppression of bone turnover can lead to an accumulation of microdamage and reduced ability to repair bone tissue. In the jawbone, which undergoes constant remodeling due to mechanical stress from chewing and dental procedures, this inhibition may be particularly detrimental. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the mechanical and structural properties of jawbone, potentially predisposing it to necrosis. Additional mechanistic pathways involve the anti-angiogenic effects of bisphosphonates. By inhibiting vascular endothelial growth factor and other angiogenic factors, Fosamax may reduce blood supply to the jawbone, contributing to tissue ischemia and necrosis. The jawbone has a relatively limited blood supply compared to other skeletal sites, making it more vulnerable to ischemic injury. Furthermore, bisphosphonates can impair the function of oral mucosal cells and immune cells, compromising the ability to fight local infections and heal after dental trauma. This is consistent with clinical observations that ONJ is often associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Factors and Causation Considerations

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms ranged from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Causation-related considerations for affected patients are important. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms of ONJ were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that ONJ can occur in the absence of bisphosphonate therapy, complicating the establishment of causation. However, a subset of patients who developed symptoms had recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), providing evidence of a drug-related effect. Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), further supporting a causal link.

Adequacy of Warnings and Clinical Implications

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, describing its association with bisphosphonates, known risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide guidance but may not fully capture the risk for all patients, particularly those with multiple risk factors. In summary, Fosamax can trigger ONJ through mechanisms involving suppressed bone turnover, altered jawbone mechanical properties, reduced blood supply, and impaired healing. The risk is influenced by duration of exposure and presence of other risk factors. While warnings exist, affected patients should be aware of the potential for ONJ and discuss preventive measures with their healthcare providers.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the primary mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, leading to suppressed bone turnover, accumulation of microdamage, and reduced repair capacity. This is particularly detrimental in the jawbone due to constant remodeling. Additionally, anti-angiogenic effects reduce blood supply, and impaired immune function compromises healing after dental trauma (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can ONJ occur?

The time to onset of symptoms ranged from one day to several months after starting the drug. The risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.